133 related articles for article (PubMed ID: 37812362)
1. Treatment utilization and effectiveness of neoadjuvant chemotherapy comparing men and women diagnosed with breast cancer: a Swedish retrospective cohort study.
Schiza A; Fredriksson I; Sund M; Valachis A
Breast Cancer Res Treat; 2024 Jan; 203(2):235-243. PubMed ID: 37812362
[TBL] [Abstract][Full Text] [Related]
2. National trends in neoadjuvant chemotherapy utilization in patients with early-stage node-negative triple-negative breast cancer: the impact of the CREATE-X trial.
Rogers C; Cobb AN; Lloren JIC; Chaudhary LN; Johnson MK; Huang CC; Teshome M; Kong AL; Singh P; Cortina CS
Breast Cancer Res Treat; 2024 Jan; 203(2):317-328. PubMed ID: 37864105
[TBL] [Abstract][Full Text] [Related]
3. Utilization, duration, and outcomes of neoadjuvant endocrine therapy in the United States.
Pariser AC; Sedghi T; Soulos PR; Killelea B; Gross CP; Mougalian SS
Breast Cancer Res Treat; 2019 Nov; 178(2):419-426. PubMed ID: 31401686
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Chemotherapy Use for Nonmetastatic Breast Cancer at Five Public South African Hospitals and Impact on Time to Initial Cancer Therapy.
O'Neil DS; Nietz S; Buccimazza I; Singh U; Čačala S; Stopforth LW; Joffe M; Jacobson JS; Neugut AI; Crew KD; Ruff P; Cubasch H
Oncologist; 2019 Jul; 24(7):933-944. PubMed ID: 30518615
[TBL] [Abstract][Full Text] [Related]
5. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
6. Refining the indications for neoadjuvant chemotherapy for patients with HER2+ breast cancer: A single institution experience.
Pomponio MK; Burkbauer L; Goldbach M; Nazarian SM; Xie F; Clark AS; Matro JM; Fox KR; Shulman LN; Keele LJ; Tchou J
J Surg Oncol; 2020 Mar; 121(3):447-455. PubMed ID: 31919848
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
Chen Y; Chen K; Xiao X; Nie Y; Qu S; Gong C; Su F; Song E
BMC Cancer; 2016 May; 16():320. PubMed ID: 27198767
[TBL] [Abstract][Full Text] [Related]
8. Does the time from diagnostic biopsy to neoadjuvant chemotherapy affect the rate of pathologic complete response in stages I-III breast cancer?
Le D; Eslami M; Li H; Hajjaj O; Chia S; Simmons C
Curr Oncol; 2020 Jun; 27(3):e265-e270. PubMed ID: 32669932
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses.
Yang Y; Im SA; Keam B; Lee KH; Kim TY; Suh KJ; Ryu HS; Moon HG; Han SW; Oh DY; Han W; Kim TY; Park IA; Noh DY
BMC Cancer; 2016 Jul; 16():515. PubMed ID: 27444430
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy use trends among older women with breast cancer: 2010-2017.
Zhang H; Barner JC; Moczygemba LR; Rascati KL; Park C; Kodali D
Breast Cancer Res Treat; 2022 Jun; 193(3):695-705. PubMed ID: 35449473
[TBL] [Abstract][Full Text] [Related]
11. The effect of obesity on pathological complete response and survival in breast cancer patients receiving uncapped doses of neoadjuvant anthracycline-taxane-based chemotherapy.
Farr A; Stolz M; Baumann L; Bago-Horvath Z; Oppolzer E; Pfeiler G; Seifert M; Singer CF
Breast; 2017 Jun; 33():153-158. PubMed ID: 28395233
[TBL] [Abstract][Full Text] [Related]
12. Treatment times in breast cancer patients receiving neoadjuvant vs adjuvant chemotherapy: Is efficiency a benefit of preoperative chemotherapy?
Melchior NM; Sachs DB; Gauvin G; Chang C; Wang CE; Sigurdson ER; Daly JM; Aggon AA; Hayes SB; Obeid EI; Bleicher RJ
Cancer Med; 2020 Apr; 9(8):2742-2751. PubMed ID: 32096915
[TBL] [Abstract][Full Text] [Related]
13. Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?
Andrade WP; Lima EN; Osório CA; do Socorro Maciel M; Baiocchi G; Bitencourt AG; Fanelli MF; Damascena AS; Soares FA
Eur J Surg Oncol; 2013 Dec; 39(12):1358-63. PubMed ID: 24120422
[TBL] [Abstract][Full Text] [Related]
14. Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2/CEP17 ratio in HER2 overexpressing breast cancer: analysis of the National Cancer Database (NCDB).
Greenwell K; Hussain L; Lee D; Bramlage M; Bills G; Mehta A; Jackson A; Wexelman B
Breast Cancer Res Treat; 2020 Jun; 181(2):249-254. PubMed ID: 32277375
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with radiologic-pathologic discordance in magnetic resonance imaging after neoadjuvant chemotherapy for breast cancer.
Kwon MR; Chu J; Kook SH; Kim EY
Clin Imaging; 2022 Sep; 89():1-9. PubMed ID: 35654000
[TBL] [Abstract][Full Text] [Related]
16. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.
Barron AU; Hoskin TL; Day CN; Hwang ES; Kuerer HM; Boughey JC
JAMA Surg; 2018 Dec; 153(12):1120-1126. PubMed ID: 30193375
[TBL] [Abstract][Full Text] [Related]
17. Patients achieved pCR during neoadjuvant chemotherapy had better outcome than adjuvant chemotherapy setting in breast cancer: A comparative study.
Chen J; Jin L; Chen L; Bian Z; Li Z; Cao S; Zhou J; Xu L; Zhao W; Wang Q
Cancer Treat Res Commun; 2023; 36():100719. PubMed ID: 37187018
[TBL] [Abstract][Full Text] [Related]
18. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
19. Utilization of neoadjuvant chemotherapy varies in the treatment of women with invasive breast cancer.
Onitilo AA; Onesti JK; Single RM; Engel JM; James TA; Aiello Bowles EJ; Spencer Feigelson H; Barney T; McCahill LE
PLoS One; 2013; 8(12):e84535. PubMed ID: 24376822
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of a Multidisciplinary Team in the Management of Patients with Early-Stage Breast Cancer Undergoing Neoadjuvant Chemotherapy at a Community Cancer Center.
Bhardwaj PV; Mason H; Kaufman SA; Visintainer P; Makari-Judson G
Curr Oncol; 2023 May; 30(5):4861-4870. PubMed ID: 37232824
[No Abstract] [Full Text] [Related]
[Next] [New Search]
